---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-015941"
form_type: "8-K"
ticker: "LTRN"
cik: "0001763950"
company_name: "Lantern Pharma Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:41:38.758019+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lantern Pharma Q1 net loss $3.9M; cash $51.5M; first patient dosed in Phase 2 Harmonic trial

## Summary
- Cash, cash equivalents, and marketable securities $51.5M as of March 31, 2023; cash runway into 2025.
- Net loss $3.9M ($0.36/share) for Q1 2023 vs $4.1M ($0.38/share) for Q1 2022.
- Dosed first patient in Phase 2 Harmonic trial for never-smoker NSCLC; multiple additional sites expected by mid-2023.
- IND submission for LP-184 anticipated this week; Phase 1A basket trial targeted for mid-2023 in solid tumors and CNS cancers.
- Formed subsidiary Starlight Therapeutics to develop LP-184 (STAR-001) for CNS and brain cancers.

## SEC filing metadata
- accession: 0001493152-23-015941
- form_type: 8-K
- ticker: LTRN
- cik: 0001763950
- company_name: Lantern Pharma Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1763950/000149315223015941/0001493152-23-015941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1763950/000149315223015941/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-015941
- JSON: https://secwatch.observer/filing/0001493152-23-015941.json
- Plain text: https://secwatch.observer/filing/0001493152-23-015941.txt

## Key facts
- Earnings Releases
  Lantern Pharma Inc. reported financial results for first quarter ended March 31, 2023.
  - Period: first quarter ended March 31, 2023
  - Result: reported results
  source text: will issue a press release announcing its financial results for the first quarter ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1763950/000149315223015941/0001493152-23-015941-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.